About Celemics
Celemics is a publicly listed company based in Seoul (South Korea) founded in 2010. Novel sequencing technologies for NGS-based genome analysis are developed. The company has 42 employees. Its Indian entity Celemics India Private Limited reported revenue of ₹2.10 Cr. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified.
Company details
Celemics was founded in 2010 and is based in Seoul, South Korea, within the biotechnology sector focused on genomics. Novel DNA Targeted Sequencing technology is utilized to enable personalized genome analysis for clients. Kits for various sequencing methods are provided, along with BRCA testing services that examine BRCA1 and BRCA2 genes for risks associated with breast, ovarian, colorectal, endometrial, lung, gastric, and other cancers.
- Indian entity revenue₹2.10 Cr
FY 2025 · +742219% YoY
- Indian entity net loss-₹50.1 Lakh
FY 2025 · -24% margin
- Indian entity EBITDA-₹47.5 Lakh
FY 2025 · -23% margin
- Employee Count42
Associated legal entities of Celemics
Celemics operates through Celemics India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Celemics India Private Limited CIN U20299KA2023FTC181119 | Active | 18 Nov 2023 | Bangalore, Karnataka | ₹2.1 Cr | 1 | 2 | View details |
Apps and channels of Celemics
its YouTube channel CELEMICS, Inc. has 70 subscribers and 15 videos.
Videos from Celemics
The most watched videos on Celemics's YouTube channel, CELEMICS, Inc. (70 subscribers). Click a video to play it here.
More on CELEMICS, Inc..
Board of directors of Celemics India Private Limited (Celemics)
Celemics India Private Limited is the primary company behind Celemics. The board of Celemics India Private Limited currently have 2 directors; the longest-serving is Velusamy Vijayanand, appointed in 2023.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Velusamy Vijayanand DIN 10396415 | Director | 18 Nov 2023 | 2 yrs 11 mo | Celemics India Private Limited |
| Kim Hyoki DIN 10396416 | Director | 18 Nov 2023 | 2 yrs 11 mo | Celemics India Private Limited |
IPO & Listings of Celemics
Celemics is a publicly listed company on the KRX with ticker symbol 331920 in South Korea, operating in the Electronic technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Aug 2020
- Listed onKRX: 331920
- Listed entityCelemics, Inc.
- Exchange sectorElectronic technology
- ISINKR7331920009
- Share price9,640.00 KRW (-3.7% on the day) · 2026-10-14
- Market capitalisation111,927,363,491.00 KRW
- EPS (diluted, trailing year)-1,562.36 KRW
- Volume (last session)17,391
Financials of Celemics
Figures of Celemics India Private Limited, the primary company behind Celemics, for FY 2025. Revenue was ₹2.10 Cr (+742219% year on year). Net loss was -₹50.1 Lakh (-24% margin). EBITDA was -₹47.5 Lakh (-23% margin).
- ₹2.10 CrRevenue · FY 2025 · +742219% YoY
- -₹50.1 LakhNet loss · -24% margin
- -₹47.5 LakhEBITDA · -23% margin
- ₹2.15 CrPaid-up capital
- 1Employees (provident fund records)
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 5.77B KRW | -4.04B KRW | -2.60B KRW |
| 2024 | 6.72B KRW | 12.27B KRW | -1.11B KRW |
| 2023 | 6.58B KRW | -3.88B KRW | -4.91B KRW |
| 2022 | 8.73B KRW | -4.80B KRW | -4.84B KRW |
| 2021 | 8.08B KRW | -5.24B KRW | -5.14B KRW |
Balance sheet, profit and loss, cash flow and ratios of Celemics India Private Limited are on its company page.
Detailed financial statements for Celemics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Celemics
The website of Celemics (celemics.com) receives about 6K visits a month.
- Monthly visits6K
▼ 1.1% vs previous month
Websites whose visitors overlap most with Celemics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
jtocrr.org | jtocrr.org | 100% | #1,722,189 | – | |
| biotech-careers.org | 60% | #758,383 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Celemics
Complete news archive for Celemics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Celemics
Celemics was founded in 2010.
Celemics is headquartered in Seoul, South Korea.
Celemics has 42 employees.
The primary company behind Celemics, Celemics India Private Limited, reported revenue of ₹2.10 Cr for FY 2025, up 742219% year on year.
Celemics was founded in 2010 and is based in Seoul, South Korea, within the biotechnology sector focused on genomics. Novel DNA Targeted Sequencing technology is utilized to enable personalized genome analysis for clients. Kits for various sequencing methods are provided, along with BRCA testing services that examine BRCA1 and BRCA2 genes for risks associated with breast, ovarian, colorectal, endometrial, lung, gastric, and other cancers.
Yes, Celemics is publicly traded on KRX under the ticker symbol 331920.
Celemics operates through Celemics India Private Limited.
The legal entities of Celemics currently have 2 directors, including Velusamy Vijayanand, Kim Hyoki.